Method for simultaneously determining nine anticoagulant drugs and ticagrelor active metabolite AR-C124910XX in plasma

Through the combination of LC-MS/MS technology, combined with ZnSO4 solution and solid-phase extraction plate, and the combination of formic acid-regulated mobile phase, the problem of being unable to detect multiple anticoagulants at the same time with high sensitivity is solved, and the problem of high sensitivity detection of multiple anticoagulants is achieved. Accurate individualized monitoring of warfarin and other drugs improves the accuracy of treatment.

CN119000933APending Publication Date: 2024-11-22YUJING TECH SHANGHAI CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411122035.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-15
Publication Date
2024-11-22

AI Technical Summary

Technical Problem

The prior art cannot detect warfarin, clopidogrel, rivaroxaban, edoxaban, dabigatran, apixaban, rosuvastatin, atorvastatin, and ticagrere at the same time with high sensitivity. Luo and its metabolite AR-C124910XX lead to inaccurate test results or failure to reach the required lower limit of quantification, affecting the individualized administration of anticoagulant therapy.

Method used

Using an LC-MS/MS-based method, the gradient elution procedure is optimized by selecting appropriate pretreatment methods and mobile phase combinations, including using ZnSO4 solution and solid phase extraction plate for sample extraction, and adding formic acid as additive to the mobile phase. To achieve complete separation of target compounds and high sensitivity detection.

Benefits of technology

The simultaneous detection of warfarin, clopidogrel, rivaroxaban, edoxaban, dabigatran, apixaban, rosuvastatin, atorvastatin and metabolite AR-C124910XX was achieved. The sensitivity reaches or exceeds 2ng/mL, meets clinical needs and improves the accuracy and efficiency of the detection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119000933A_ABST
    Figure CN119000933A_ABST
Patent Text Reader

Abstract

The invention discloses a method for simultaneously detecting and measuring nine anticoagulant drugs and ticagrelor active metabolites AR-C124910XX in blood plasma with high sensitivity. The nine anticoagulant drugs are warfarin, clopidogrel, rivaroxaban, eldoxaban, dabigatran, apixaban, rosuvastatin, atorvastatin and ticagrelor. The invention also discloses a method for simultaneously detecting and measuring the nine anticoagulant drugs and the ticagrelor active metabolites AR-C124910XX in the blood plasma with high sensitivity. Comprising the following steps: taking a plasma sample, adding an internal standard solution, mixing and centrifuging, and taking supernate; adding the supernate into an activated solid-phase extraction plate, and further extracting and purifying; injecting the eluent into a liquid chromatograph-mass spectrometer for analysis; the volume ratio of acetonitrile to methanol in a chromatographic detection organic phase is 3 / 7-1 / 9, and the organic phase contains 0.1-1% of formic acid additive; and calculating the content of each medicine in the sample based on a standard curve method. By adopting the method disclosed by the invention, the simultaneous determination of nine anticoagulant drugs and one active metabolite is realized, and meanwhile, the high sensitivity is achieved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of liquid chromatography-tandem mass spectrometry (LC-MS / MS) detection technology, and to a method for the simultaneous determination of warfarin, clopidogrel, rivaroxaban, edoxaban, dabigatran, apixaban, rosuvastatin, atorvastatin, ticagrelor, and the active metabolite AR-C124910XX of ticagrelor with high sensitivity based on LC-MS / MS. Background Technology

[0002] Warfarin is a coumarin anticoagulant that inhibits vitamin K epoxide reductase in the liver, preventing the activation of inactive oxidized vitamin K into its reduced form. This, in turn, inhibits the synthesis of coagulation factors II, VII, IX, and X in the liver, and it is widely used in the prevention and treatment of thromboembolic diseases. Clopidogrel is a widely used platelet receptor inhibitor, primarily used to treat circulatory disorders such as stroke and acute coronary syndrome. After metabolism, it selectively binds to the adenosine diphosphate receptor P2Y12 on the platelet membrane surface, thereby inhibiting platelet aggregation. Rivaroxaban is a factor Xa inhibitor, mainly used to prevent various acute and chronic thrombotic diseases, as well as for the prevention of stroke in patients with atrial fibrillation, secondary prevention of acute coronary syndrome, and prevention of venous thromboembolism (VTE) in hospitalized medical patients. Edoxaban is a novel oral direct inhibitor of coagulation factor Xa, launched in China in 2018. It is primarily used for the prevention and treatment of non-valvular atrial fibrillation (NVAF) and venous thromboembolism (VTE). Compared to the traditional anticoagulant warfarin, it is relatively expensive. Compared to other novel oral anticoagulants (NOACs), it has the shortest time on the market, limited clinical experience, and is prone to inappropriate use, which can lead to serious consequences. Dabigatran is a novel oral anticoagulant, belonging to the non-peptide direct thrombin inhibitor class. It prevents thrombosis by blocking the conversion of fibrinogen to fibrin in the coagulation reaction and is now used for stroke prevention and systemic embolism prevention in adult patients with non-valvular atrial fibrillation. Apixaban is a potent and highly selective factor Xa active site inhibitor. It indirectly inhibits prothrombinase activity and platelet aggregation by inhibiting free and thrombus-bound factor Xa, thereby inhibiting thrombus formation. Clinically, it is used to prevent venous thromboembolism after elective hip or knee replacement surgery. Rosuvastatin and atorvastatin are widely used statins in clinical practice to treat hyperlipidemia and reduce the risk of atherosclerotic cardiovascular disease. Statins inhibit 3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CoA reductase), which is responsible for converting HMG-CoA to mevalonate. Ticagrelor is a cyclopentyltriazine antiplatelet drug, a novel and potent antagonist of the P2Y12 receptor. It exhibits reversible, concentration-dependent inhibition of ADP-induced platelet aggregation. It is an oral antiplatelet drug widely used clinically for acute coronary syndrome (ACS). Ticagrelor rapidly produces a metabolite with the same activity, AR-C124910XX, under the action of the CYP3A4 enzyme.

[0003] Warfarin, as the primary oral medication for long-term anticoagulation therapy, has a narrow therapeutic dose range, significant individual variability, and its efficacy is easily affected by non-genetic factors such as age, sex, body weight, and medication. This can lead to side effects such as insufficient efficacy causing thrombosis and excessive dosage causing bleeding, thus requiring clinical monitoring. Over the past decade, direct oral anticoagulants (DOACs) have been gradually introduced into Level 1 and 2 clinical practice globally, with efficacy and safety comparable to or better than vitamin K antagonists (VKAs). DOACs are used to prevent stroke and systemic thromboembolic events in non-valvular atrial fibrillation (NVAF), for the treatment and secondary prevention of venous thromboembolic events (VTE), for primary prevention of VTE after orthopedic surgery, or for primary prevention of VTE in patients with symptomatic peripheral artery disease after lower limb revascularization closest to the peripheral artery disease. DOACs directly, specifically, and reversibly inhibit activating factor X (FXa, rivaroxaban, apixaban, and edoxaban) or thrombin (dabigatran). Compared to VKAs (warfarin), DOACs offer predictable pharmacokinetic and pharmacodynamic characteristics, a broad therapeutic index, and limited drug-drug and food-drug interactions. Clinicians face numerous challenges in patients receiving DOACs, particularly in cases of acute massive bleeding or emergency surgery. In such clinical situations, assessing DOAC plasma concentrations is crucial when considering specific antidotes. Monitoring anticoagulant efficacy is necessary for some patients with renal or hepatic impairment, advanced age, or low body weight, allowing for timely adjustments to anticoagulation intensity. Because clinically used anticoagulants have narrow therapeutic windows and exhibit significant individual variability across different populations, efficacy is easily influenced by patient age, sex, concomitant medications, and hepatic or renal function. The risk of bleeding after administration is related to peak plasma concentration, while the risk of embolism is related to trough plasma concentration. Therefore, establishing a method to measure drug concentrations in patients is significant, providing data for individualized dosing.

[0004] Thrombosis is a cause or complication of many diseases, such as pulmonary thromboembolism, cerebrovascular disease, atherosclerosis, coronary heart disease, and deep vein thrombosis after surgery or trauma. Anticoagulants prevent blood clotting and thrombus formation, and are commonly used in atrial fibrillation, post-artificial valve replacement surgery, peripheral venous thrombosis, pulmonary embolism, disseminated intravascular coagulation (DIC), and acute myocardial infarction (AMI). Therefore, anticoagulants are crucial in clinical practice. However, due to the narrow therapeutic window and significant individual variability of anticoagulants, achieving precise treatment in clinical practice presents many challenges. In many cases, conservative drug administration is chosen to prevent bleeding events, which does not achieve optimal anticoagulation effects. To ensure patients receive the best treatment plan, blood drug concentration monitoring is necessary to quickly guide adjustments to the treatment plan and provide data for individualized dosing. This necessitates the technological advancement of rapid detection of commonly used anticoagulants.

[0005] As is well known, the prerequisite for rapid testing is the simultaneous determination of warfarin, clopidogrel, rivaroxaban, edoxaban, dabigatran, apixaban, rosuvastatin, atorvastatin, ticagrelor, and its metabolite AR-C124910XX using the same method. The abbreviation for clinical test reporting time is "TAT," which stands for "Turnaround Time," meaning the time from when the patient undergoes testing or sample collection to when the medical institution finally provides the test results. A shorter TAT is often crucial for emergencies and timely diagnosis. If the simultaneous determination of common anticoagulants cannot be achieved, the reporting time will be extended by at least 4-8 hours, significantly delaying adjustments to the patient's treatment plan.

[0006] Simultaneous detection of anticoagulant blood concentrations is urgently needed. Although numerous articles and patents mention methods for detecting warfarin, dabigatran, clopidogrel, rivaroxaban, apixaban, edoxaban, and ticagrelor alone, a systematic search of currently published academic articles, patent applications, and other publicly available materials has revealed no methods for simultaneously detecting these anticoagulants and their active metabolites.

[0007] The chemical structural formulas of the 10 compounds are as follows:

[0008]

[0009] A. AR-C124910XX;

[0010]

[0011] B. Ticagrelor;

[0012]

[0013] C. Warfarin

[0014]

[0015] D. Clopidogrel

[0016]

[0017] E. Livarsaban

[0018]

[0019] F, Aidoshaban

[0020]

[0021] G. Dabiga Group

[0022]

[0023] H, Atorvastatin

[0024]

[0025] I. Apixaban

[0026]

[0027] J. Rosuvastatin

[0028] The following is a summary of the routine methods and main difficulties in the simultaneous determination of warfarin, clopidogrel, rivaroxaban, edoxaban, dabigatran, apixaban, rosuvastatin, atorvastatin, ticagrelor, and its metabolite AR-C124910XX:

[0029] 1) First, based on the peak and trough concentrations and therapeutic window of these 10 compounds after administration, the lower limit of quantitation (LOQ) of the standard curve was determined, and a matrix standard curve containing blank plasma was prepared. During the extraction of the matrix standard curve, conventional precipitation reagents such as methanol and acetonitrile could not achieve a signal-to-noise ratio (SNR) of over 10 for the LQ of all compounds. When methanol was used as the precipitant, the responses of edoxaban, atorvastatin, rosuvastatin, and ticagrelor were poor, with no peaks observed for STD1 and STD2. When acetonitrile was used as the precipitant, the responses of dabigatran, ticagrelor, and their metabolites were poor. When the injection volume was increased to 15–20 μL, the solvent effect was significantly enhanced, resulting in prominent peak fronts and poor peak shape for apixaban and dabigatran, leading to inaccurate detection results.

[0030] 2) After taking anticoagulants, peak concentrations are associated with unexpected bleeding events, while trough concentrations are associated with thrombotic events. Therefore, it is necessary to monitor both peak and trough concentrations after medication to avoid excessive dosage leading to bleeding or insufficient dosage failing to achieve the desired anticoagulant effect, resulting in thrombotic events. Consequently, high sensitivity is required for the detection, necessitating very low limits of quantitation (LOQs). For warfarin and ticagrelor, the LQ needs to be 2 ng / mL; for apixaban, it needs to be 1.5 ng / mL; for rivaroxaban, edoxaban, dabigatran, and AR-C124910XX, it needs to be 1 ng / mL; for clopidogrel, it needs to be 0.2 ng / mL; and for atorvastatin and rosuvastatin, it needs to be 0.25 ng / mL. In existing technologies, the quantitation range for simultaneous determination of rivaroxaban, edoxaban, and dabigatran is 2-500 ng / mL. However, existing methods for detecting rosuvastatin, atorvastatin, ticagrelor, and AR-C124910XX fail to meet the limits of quantitation established based on trough concentration. Because these nine anticoagulant metabolites (AR-C124910XX) need to be measured simultaneously, the pretreatment methods for all ten compounds must be consistent. However, existing methods such as protein precipitation and liquid-liquid extraction cannot meet the limits of quantitation for the simultaneous determination of these ten compounds.

[0031] 3) When injecting a mixed series of standards, the standard curves for ticagrelor and AR-C124900XX were found to be non-linear. When injecting individual standards of both, MRM ion channel interference was observed between ticagrelor and its active metabolite AR-C124910XX. When ticagrelor standard was injected alone, and then the MRM channel peak of metabolite AR-C124910XX was extracted, a very distinct peak was observed with the same retention time as ticagrelor. When AR-C124910XX standard was injected alone, and then the MRM channel peak of ticagrelor was extracted, a very strong peak was observed with the same retention time as AR-C124910XX. Typical chromatograms are shown below. Figure 1 Ticagrelor and AR-C124910XX have very similar structures and retention times. To resolve the interference between their channels, their chromatographic peaks need to be completely separated. When using acetonitrile as the mobile phase, various gradients were tried, but complete separation was still not achieved.

[0032] 4) When protein precipitation was used to extract plasma-containing matrix standards, the sensitivity of ticagrelor, AR-C124910XX, and rosuvastatin all failed to reach the required trough concentration. Adding 0.1%–2% formic acid as a precipitant did not improve the results. Typical chromatograms are shown below. Figure 2When liquid-liquid extraction was used, the responses of dabigatran and edoxaban were poor. Attempts to change the extraction reagents, such as ethyl acetate, tert-butyl methyl ether, or different ratios of ethyl acetate and tert-butyl methyl ether (1 / 1, 6 / 4, 7 / 3, 8 / 2), and to add different proportions of additives such as 0.5%–5% formic acid, failed to improve the responses of dabigatran and edoxaban. Typical chromatograms are shown below. Figure 3 Commonly used pretreatment methods cannot simultaneously achieve the required trough concentrations for each of these 10 compounds.

[0033] A search of existing patent literature revealed that prior patent CN114755348A established a method for the separate detection of warfarin with a limit of quantitation (LOQ) of 200 ng / mL, employing a protein precipitation extraction method. In contrast, the LOQ of this invention is 2 ng / mL. Furthermore, the protein precipitation method, whether using common organic reagents such as methanol and acetonitrile or strong acids such as sulfosalicylic acid, cannot meet the LOQ requirements for 10 compounds. When methanol or acetonitrile is used as the precipitant, rivaroxaban, rosuvastatin, atorvastatin, ticagrelor, and AR-C124910XX cannot achieve the LOQ required for trough concentration, thus failing to meet the requirement for simultaneous detection of 10 anticoagulant-related compounds as described in this invention.

[0034] The prior patent CN118130678A established a method for detecting clopidogrel, rosuvastatin, and atorvastatin. The extraction method used was methanol precipitation of proteins, followed by centrifugation, nitrogen drying of the supernatant, and injection analysis. This method was time-consuming and did not use isotope internal standards for quantification. When using methanol precipitation of proteins, rivaroxaban, rosuvastatin, atorvastatin, ticagrelor, and AR-C124910XX could not achieve the lower limit of quantitation (LOQ) based on the drug trough concentration, making them unsuitable for the purpose of simultaneously determining 10 anticoagulant-related components in this invention.

[0035] The prior patent CN113092628A established a method for detecting rivaroxaban, edoxaban, apixaban, and dabigatran. This invention uses methanol or acetonitrile as the precipitating reagent, and the linear range of the four compounds in this invention is 2-500 ng / mL. However, using the method in this invention to detect rosuvastatin, atorvastatin, ticagrelor, and AR-C124910XX fails to detect the lower limit of quantitation established based on trough concentration, thus failing to achieve the objective of simultaneously detecting 10 anticoagulant-related components as described in this invention.

[0036] A prior patent, CN115372499A, established a method for ticagrelor and AR-C124910XX. In this invention, methanol or acetonitrile was selected as the precipitant. The linear range for ticagrelor was 11.70-2500 ng / mL, and the linear range for the metabolite AR-C124910XX was 11.72-2000 ng / mL. However, the method in this patent cannot meet the lower limit of quantitation requirements for other compounds.

[0037] Therefore, whether searching patents or published literature at home and abroad, existing methods cannot achieve simultaneous detection of plasma phloroglucinol, clopidogrel, rivaroxaban, edoxaban, dabigatran, apixaban, rosuvastatin, atorvastatin, ticagrelor, and metabolite AR-C124910XX. This is because these methods cannot achieve sufficient extraction of 10 compounds simultaneously, failing to meet the trough concentration requirement for the lower limit of quantification, thus affecting the accurate quantification of trough concentration.

[0038] In summary, with current traditional separation techniques, it is difficult to achieve simultaneous analysis of warfarin, clopidogrel, rivaroxaban, edoxaban, dabigatran, apixaban, rosuvastatin, atorvastatin, ticagrelor, and its metabolite AR-C124910XX. However, based on the needs of practical work, it is necessary to achieve simultaneous analysis of these 10 compounds, and high sensitivity is required to meet the requirements. Summary of the Invention

[0039] The purpose of this invention is to overcome the problems of existing technologies that cannot simultaneously detect warfarin, clopidogrel, rivaroxaban, edoxaban, dabigatran, apixaban, rosuvastatin, atorvastatin, ticagrelor, and its metabolite AR-C124910XX, and that the detection sensitivity is insufficient. This invention provides a method based on LC-MS / MS for the simultaneous determination of warfarin, clopidogrel, rivaroxaban, edoxaban, dabigatran, apixaban, rosuvastatin, atorvastatin, ticagrelor, and its metabolite AR-C124910XX in human plasma. Under the premise of simultaneous determination, the sensitivity of these 10 drugs or active metabolites is at least 2 ng / mL for warfarin, 0.2 ng / mL for clopidogrel, 1 ng / mL for rivaroxaban, 1.5 ng / mL for apixaban, 1 ng / mL for dabigatran, 1 ng / mL for edoxaban, 2 ng / mL for ticagrelor, and AR-C124910XX. The concentrations were 1 ng / mL for atorvastatin, 0.25 ng / mL for rosuvastatin, and below 0.25 ng / mL (the current sensitivity is sufficient, so further dilution was not conducted to investigate the limit of sensitivity of this method; however, if necessary, the detection limit could be further improved using this method). This invention, by selecting a suitable pretreatment method and adding specific additives to the pretreatment reagents, allows warfarin, clopidogrel, rivaroxaban, edoxaban, dabigatran, apixaban, rosuvastatin, atorvastatin, ticagrelor, and its metabolite AR-C124910XX to be analyzed simultaneously in a single test. The detection method of this invention features high sensitivity, specificity, simple operation, and short time consumption, making it more suitable for solving clinical problems.

[0040] The objective of this invention is achieved through the following technical solution:

[0041] This invention provides a method for simultaneously detecting nine anticoagulant drugs and the active metabolite of ticagrelor, AR-C124910XX, in plasma. The nine anticoagulant drugs are warfarin, clopidogrel, rivaroxaban, edoxaban, dabigatran, apixaban, rosuvastatin, atorvastatin, and ticagrelor. Under the premise of simultaneous determination, the sensitivity of the 10 drugs or active metabolites is at least below 2 ng / mL for warfarin, 0.2 ng / mL for clopidogrel, 1 ng / mL for rivaroxaban, 1.5 ng / mL for apixaban, 1 ng / mL for dabigatran, 1 ng / mL for edoxaban, 2 ng / mL for ticagrelor, 1 ng / mL for AR-C124910XX, 0.25 ng / mL for atorvastatin, and 0.25 ng / mL for rosuvastatin. (The current sensitivity is sufficient; therefore, this invention did not further dilute the method to investigate its limiting sensitivity. However, if necessary, the detection limit can be further improved using this method.) The method includes the following steps:

[0042] S1. Take a plasma sample, add an internal standard solution, mix, centrifuge, and take the supernatant; the internal standard solution is prepared by dissolving the internal standard in a ZnSO4 solution containing formic acid.

[0043] S2. Add the supernatant to the activated solid-phase extraction plate and further extract and purify it using a solid-phase extraction device;

[0044] S3. Inject the eluent into a liquid chromatography-mass spectrometry system for analysis;

[0045] The mobile phase used for the chromatographic detection includes an aqueous phase and an organic phase. The aqueous phase is an aqueous solution containing 0.1-1 wt.% formic acid, and the organic phase is an acetonitrile / methanol mixture containing 0.1-1 wt.% formic acid. The volume ratio of acetonitrile to methanol in the organic phase is 3 / 7-1 / 9.

[0046] S4. Calculate the contents of phloretin, clopidogrel, rivaroxaban, edoxaban, dabigatran, apixaban, rosuvastatin, atorvastatin, ticagrelor and its metabolite AR-C124910XX in the sample based on the standard curve method.

[0047] In one embodiment of the present invention, the concentration of ZnSO4 in the internal standard solution of S1 is 0.2M to 0.5M, and the content of formic acid is 0.1wt.% to 1wt.%. The pH environment is created by using an internal standard solution containing 0.1wt.% to 1wt.% formic acid, as described in step S1.

[0048] As one embodiment of the present invention, in step S1, the centrifugation conditions are 14000 rpm for 5 minutes; the supernatant is taken within 15 to 30 minutes after centrifugation, and a second centrifugation is required if it is left for a long time.

[0049] In one embodiment of the present invention, the plasma sample volume in S1 is 100 μL.

[0050] In one embodiment of the present invention, the amount of internal standard solution added in S1 is 150-400 μL.

[0051] As one embodiment of the present invention, the internal standards in S1 are isotopic internal standards of warfarin, clopidogrel, rivaroxaban, edoxaban, dabigatran, apixaban, rosuvastatin, atorvastatin, and ticagrelor.

[0052] As one embodiment of the present invention, the internal standard for warfarin is warfarin-d5; the internal standard for clopidogrel is clopidogrel-13C6; the internal standard for rivaroxaban is rivaroxaban-d4; the internal standard for edoxaban is edoxaban-d6; the internal standard for dabigatran is dabigatran-d4; the internal standard for apixaban is apixaban-13C8; the internal standard for rosuvastatin is rosuvastatin-d3; the internal standard for atorvastatin is atorvastatin-d5; and the internal standard for ticagrelor and its active metabolite AR-C124900XX is ticagrelor-d7.

[0053] As one embodiment of the present invention, the contents of warfarin-d5, clopidogrel-13C6, rivaroxaban-d4, edoxaban-d6, dabigatran-d4, apixaban-13C8, rosuvastatin-d3, atorvastatin-d5, and ticagrelor-d7 are 40 ng / mL, 4 ng / mL, 20 ng / mL, 20 ng / mL, 20 ng / mL, 30 ng / mL, 1 ng / mL, 1 ng / mL, and 40 ng / mL, respectively.

[0054] As one embodiment of the present invention, the elution reagent in step S2 during solid-phase extraction is a 70% to 100% methanol solution containing 0.1% to 1% formic acid as an additive; the solid-phase extraction device is a negative pressure device; and the elution rate of the analyte needs to be controlled at 1 to 2 drops / second.

[0055] As one embodiment of the present invention, in step S3, 0.1%-1% formic acid is added to the mobile phase used for chromatographic detection.

[0056] Specifically, the mobile phase includes an aqueous phase and an organic phase, wherein the aqueous phase is an aqueous solution containing 0.1-1% formic acid, and the organic phase is an acetonitrile / methanol mixture containing 0.1-1% formic acid.

[0057] Furthermore, in the organic phase, the volume ratio of acetonitrile to methanol is 3 / 7 to 1 / 9. In the system of the present invention, the mobile phase with the above component ratio can better elute the target analyte and produce good peak shape.

[0058] Specifically, in step S3, the mobile phase used in liquid chromatography is mobile phase A, which is a 0.1-1% formic acid aqueous solution, and mobile phase B, which is acetonitrile / methanol (v / v, 1 / 9) (containing 0.1-1% formic acid).

[0059] As one embodiment of the present invention, the gradient elution program in S3 is as follows: 0-0.2 min, 2% B; 0.2-1.5 min, 2% B-55% B; 1.5-4.5 min, 55% B-95% B; 4.5-6 min, 95% B; 6-7.5 min, 2% B; the autosampler temperature is 8-10℃, the column temperature is 30-50℃, and the injection volume is 5 μL.

[0060] Specifically, the autosampler temperature is 8°C and the column temperature is 40°C.

[0061] In one embodiment of the present invention, the chromatographic column used in step S3 is a C18 chromatographic column.

[0062] Specifically, the C18 column used in S3 is an Xselect T3 column, with a column temperature of 30–50°C, a sample tray temperature of 8–10°C, a flow rate of 0.6 mL / min, and an injection volume of 5 μL.

[0063] Specifically, the column temperature of the chromatographic column is 40°C, and the temperature of the sample tray is 8°C.

[0064] As one embodiment of the present invention, in step S3, the mass spectrometry conditions are: in electrospray ionization positive ion mode, mass spectrometry scanning mode with multiple reaction monitoring is used.

[0065] Furthermore, the mass spectrometry conditions were as follows: ionization voltage of 5.5 kV; source temperature of 550 °C; spray gas GS1 of 60 psi; auxiliary heater GS2 of 65 psi; curtain gas of 35 psi; and collision gas of 9.

[0066] Furthermore, the ion pairs used for quantitative analysis and monitoring are:

[0067] Warfarin, m / z 309>251(+), declustering voltage: 130V, collision voltage: 25V;

[0068] Clopidogrel, m / z 322.3>155.2(+), declustering voltage: 100V, collision voltage: 40V;

[0069] Rivaroxaban, m / z 436>145.1(+), declustering voltage: 90V, collision voltage: 30V;

[0070] Edoshaban, m / z 548.2>152.2(+), declustering voltage: 100V, collision voltage: 25V;

[0071] Darbigat group, m / z 472.2>306.3(+), declustering voltage: 120V, collision voltage: 23V;

[0072] Apixaban, m / z 460.1>199.2(+), declustering voltage: 80V, collision voltage: 30V;

[0073] Rosuvastatin, m / z 482.3>258.3(+), declustering voltage: 110V, collision voltage: 40V;

[0074] Atorvastatin, m / z 559.2>440.1(+), declustering voltage: 80V, collision voltage: 42V;

[0075] Ticagrelor, m / z 523.2>293.3(+), declustering voltage: 90V, collision voltage: 30V;

[0076] AR-C124900XX, m / z 479.1>152.9(+), declustering voltage: 120V, collision voltage: 43V.

[0077] As one embodiment of the present invention, the lower and upper limits of linear detection and the standard curve equations for nine anticoagulant drugs and the active metabolite of ticagrelor AR-C124910XX in plasma are shown in Table 1 below (in the standard curve equation, y represents the peak area ratio of the analyte and the internal standard, and x represents the concentration):

[0078] Table 1. Linearity detection lower and upper limits and standard curve equations

[0079] Serial Number name Linear lower limit Linear upper limit Standard Curve Equation 1 warfarin 2ng / mL 2000ng / mL y=0.00479x+-0.00172(r=0.99605) 2 Clopidogrel 0.2 ng / mL 200ng / mL y=0.01639x+0.00714(r=0.99690) 3 Rivaroxaban 1ng / mL 1000ng / mL y=0.02525x+0.04474(r=0.99843) 4 Apixaban 1.5 ng / mL 1500ng / mL <![CDATA[y=0.00417x+2.69790e -4 (r=0.99879)]]> 5 Dabiga Group 1ng / mL 1000ng / mL <![CDATA[y=0.01223x+8.51209e -4 (r=0.99670)]]> 6 Aidoshaban 1ng / mL 1000ng / mL <![CDATA[y=0.00583x+-2.15592e -4 (r=0.99855)]]> 7 Ticagrelor 2ng / mL 2000ng / mL <![CDATA[y=0.00409x+-9.9905e -4 (r=0.99938)]]> 8 AR-C124910XX 1ng / mL 1000ng / mL <![CDATA[y=0.01136x+8.93883e -4 (r=0.9992)]]> 9 Atorvastatin 0.25 ng / mL 50 ng / mL <![CDATA[y=6.67622e -4 x+-3.9859e -4 (r=0.99830)]]> 10 rosuvastatin 0.25 ng / mL 50 ng / mL y=0.01955x+-0.01356(r=0.99431)

[0080] Compared with the prior art, the present invention has the following beneficial effects:

[0081] 1) Conventional pretreatment extraction methods were not used (common pretreatment methods include precipitating proteins with methanol or acetonitrile at 1 / 3 ratio and taking the supernatant; liquid-liquid extraction with ethyl acetate, taking the supernatant, drying it under nitrogen, and reconstituted; liquid-liquid extraction with tert-butyl methyl ether, taking the supernatant, drying it under nitrogen, and reconstituted). Based on the chemical structure and properties of 10 analytes, including warfarin, and through numerous innovative experiments, it was finally proven that ZnSO4 solution and solid-phase extraction plates can achieve simultaneous analysis of warfarin, clopidogrel, rivaroxaban, edoxaban, dabigatran, apixaban, rosuvastatin, atorvastatin, ticagrelor, and its metabolite AR-C124910XX, all with very low limits of quantitation.

[0082] 2) This invention uses methanol and acetonitrile in different proportions in the mobile phase, and also adds a large amount of additive, namely 0.1% to 1% formic acid (pH < 2). Because ticagrelor and its metabolite AR-C124910XX have extremely similar chemical structures, their retention times are very close. When a ticagrelor standard is injected alone, and then the MRM channel chromatographic peak of the metabolite AR-C124900XX is extracted, a very obvious chromatographic peak is observed, with a retention time consistent with ticagrelor. When an AR-C124900XX standard is injected alone, and then the MRM channel chromatographic peak of ticagrelor is extracted, a very strong chromatographic peak is observed, with a retention time consistent with AR-C124900XX. Therefore, in actual injection, to eliminate interference between channels, the chromatographic peaks of the two must be separated. When acetonitrile was used as the mobile phase, multiple optimization experiments and verifications failed to completely separate the two analytes. When methanol, with its relatively weak elution power, was used as the mobile phase, changing the gradient to separate the chromatograms resulted in very broad and thick peaks, affecting the accurate quantification of the analyte. Using a mixture of acetonitrile and methanol in a 3 / 7 to 1 / 9 ratio as mobile phase B, and optimizing the mobile phase gradient, achieved complete chromatographic separation while maintaining sharp and symmetrical peaks. The chromatograms of ticagrelor and its metabolite AR-C124900XX before and after changing the mobile phase composition are shown below. Figure 5 As shown, from Figure 5 It is evident that the problem of channel interference between ticagrelor and its active metabolite AR-C124900XX was resolved after changing the composition of mobile phase B.

[0083] 3) To significantly improve the sensitivity of dabigatran, rosuvastatin, and atorvastatin, and to improve the peak shape of dabigatran, this invention, through multiple optimization experiments and verifications, added 0.1%–1% formic acid as an additive to the pretreatment reagent, i.e., the internal standard solution. The presence of the additive significantly improved the extraction efficiency of dabigatran, rosuvastatin, atorvastatin, rivaroxaban, etc., meeting the requirements of the lower limit of quantitation (LOQ), which would otherwise not be met. Simultaneously, the peak shape of dabigatran was significantly improved. The results before and after adding 0.1%–1% of the additive to the internal standard solution are compared in Table 2 and [Table data missing]. Figure 6 ( Figure 6 The typical chromatograms before and after adding 0.1% formic acid as an additive to the internal standard solution are shown. Attached Figure Description

[0084] Other features, objects and advantages of the present invention will become more apparent upon reading the detailed description of non-limiting embodiments with reference to the following drawings:

[0085] Figure 1This is a typical chromatogram showing the mutual interference between the AR-C124910XX and ticagrelor MRM channels in Experimental Example 3;

[0086] Figure 2 The typical chromatograms of AR-C124910XX, ticagrelor, and rosuvastatin lower limits of quantification in Experimental Example 1, when acetonitrile was used as the protein precipitation reagent and 0.1% formic acid was added;

[0087] Figure 3 Typical chromatograms of rivaroxaban, rosuvastatin, ticagrelor, atorvastatin, and AR-C124910XX in Experimental Example 1 when methanol was used as the precipitating agent;

[0088] Figure 4 The typical chromatograms for the lower limits of quantification of dabigatran and edoxaban when using ethyl acetate as the extraction reagent and adding 1% formic acid during liquid-liquid extraction in Example 2 are shown.

[0089] Figure 5 Typical chromatograms of ticagrelor and AR-C124910XX before and after changing the mobile phase in Experimental Example 3;

[0090] Figure 6 This is a typical chromatogram of the lower limit of quantitation before and after adding the additive to the internal standard solution in Experiment Example 2;

[0091] Figure 7 This is a typical chromatogram of acetonitrile as the mobile phase in Experimental Example 3;

[0092] Figure 8 Typical chromatograms of the 10 compounds in Example 1;

[0093] Figure 9 The chromatograms show the lower limits of quantitation (LLOQ) for the ten compounds in Example 2. Detailed Implementation

[0094] Based on the significant differences in polarity among ten analytes—warfarin, clopidogrel, rivaroxaban, edoxaban, dabigatran, apixaban, rosuvastatin, atorvastatin, ticagrelor, and its metabolite AR-C124910XX—and considering the relatively strong polarity of dabigatran and the weaker polarity of ticagrelor, its active metabolite AR-C124910XX, atorvastatin, and rosuvastatin, this invention attempts to use the heavy metal salt ZnSO4 as a precipitating agent and further purify the biological samples using a solid-phase extraction plate.

[0095] This invention selects ZnSO4 as the precipitating agent before solid-phase extraction (SPE) plate preparation, which can accommodate the responses of 10 compounds with significantly different chemical properties and meet the limit of quantitation (LOQ) requirement. Furthermore, this invention found that while using zinc sulfate as a precipitant provides a better balance of responses than acetonitrile, methanol, sulfosalicylic acid, and trichloroacetic acid, it still cannot meet the requirement of a signal-to-noise ratio of 10 for rivaroxaban and rosuvastatin. Figure 6 As shown. Furthermore, there is inter-channel interference between ticagrelor and its metabolite AR-C124910XX. Ticagrelor elutes at the MRM channel of every AR-C124910XX, therefore, complete chromatographic separation is necessary for accurate quantification. Also, because their chemical structures are very similar and their retention times are extremely close, adjusting the liquid phase gradient too gently broadens the peaks, and they are still not completely separated. a. In this invention, zinc sulfate was chosen as the precipitant, and 0.1%–1% formic acid was added as an additive to modify the properties of the compounds. The response of all 10 compounds before and after the addition was improved by more than two times, such as... Figure 6 As shown in Figure b. To address the channel interference issue between ticagrelor and AR-C124910XX, mobile phase B was replaced. A methanol / acetonitrile ratio of 9 / 1 to 7 / 3 was chosen as the organic phase reagent. This reduced the elution power of mobile phase B, improved the selectivity for ticagrelor and AR-C124910XX, and the presence of acetonitrile resulted in sharper peaks and more accurate quantification for each compound. Results before and after changing the mobile phase are shown in Figure b. Figure 5 As shown.

[0096] The present invention is further illustrated by the following experimental examples and embodiments, but any embodiment or combination thereof should not be construed as limiting the scope or implementation of the present invention. Without departing from the spirit and scope of the present invention, those skilled in the art can make any modifications or changes to the technical solutions of the present invention, and such modifications and changes are also included within the scope of the present invention.

[0097] Unless otherwise specified in the experimental examples and embodiments, the conditions were performed under standard conditions or as recommended by the manufacturer. All reagents or instruments without a specified manufacturer are commercially available, standard products. Numerous specific details are provided in the following detailed embodiments to better illustrate the invention. Those skilled in the art should understand that the invention can be practiced even without certain specific details.

[0098] Experimental Example 1

[0099] This experimental example uses the same chromatography-mass spectrometry system to simultaneously detect nine anticoagulant drugs and ticagrelor active metabolites in plasma.

[0100] Step 1: Take 100 μL of plasma sample and accurately add 300 μL of internal standard solution (the internal standard solution is prepared with acetonitrile and contains warfarin-d5, clopidogrel-13C6, rivaroxaban-d4, edoxaban-d6, dabigatran-d4, apixaban-13C8, rosuvastatin-d3, atorvastatin-d5, and ticagrelor-d7, with concentrations of 40 ng / mL, 4 ng / mL, 20 ng / mL, 20 ng / mL, 20 ng / mL, 30 ng / mL, 1 ng / mL, 1 ng / mL, and 40 ng / mL, respectively). Vortex for 3 min, centrifuge at 14000 rpm at 4℃ for 10 min, and take 200 μL of the supernatant.

[0101] Step 2: Analysis was performed using liquid chromatography-mass spectrometry (LC-MS). The gradient elution program was: 0-0.2 min, 2% B; 0.2-4.5 min, 2% B-90% B; 4.5-6 min, 90% B; 4.5-6 min, 90% B; 6-7.5 min, 2% B. The autosampler temperature was 8℃, and the C18 column used was an Xselect T3 column with a column temperature of 40℃. The injection volume was 2 μL, and the flow rate was 0.6 mL / min. Electrospray ionization (ESI) in positive ion mode was used, employing multiple reaction monitoring (MRM) mass spectrometry. Further, the mass spectrometry conditions were: ionization voltage 5.5 kV; source temperature 550℃; spray gas GS1 60 psi; auxiliary heater GS2 65 psi; curtain gas 35 psi; collision gas 9.

[0102] This experiment first established the lower limit of quantitation (LDQ) for the standard curve based on the peak and trough concentrations and therapeutic window of these 10 compounds: warfarin 2 ng / mL, clopidogrel 0.2 ng / mL, rivaroxaban 1 ng / mL, apixaban 1.5 ng / mL, dabigatran 1 ng / mL, edoxaban 1 ng / mL, ticagrelor 2 ng / mL, AR-C124910XX 1 ng / mL, atorvastatin 0.25 ng / mL, and rosuvastatin 0.25 ng / mL. A matrix standard curve containing blank plasma was prepared. During the extraction of the matrix standard curve, conventional precipitation reagents such as methanol and acetonitrile could not achieve a signal-to-noise ratio (SNR) of over 10 for all compounds. When acetonitrile was used as the precipitation reagent according to the above steps, the responses of dabigatran, rosuvastatin, ticagrelor, and their metabolite AR-C124910XX were very poor, and the sensitivity did not meet the trough concentration requirements. Adding 0.1% formic acid to acetonitrile did not improve the results; the limit of quantification did not elute. A typical chromatogram is shown below. Figure 2 When the injection volume is increased to 15–20 μL, the solvent effect is significantly enhanced, and the chromatographic peaks of apixaban and dabigatran show obvious leading edges and poor peak shapes, resulting in inaccurate detection results.

[0103] When the precipitating reagent in step 1 above was replaced with methanol, the responses of rivaroxaban, atorvastatin, rosuvastatin, ticagrelor, and AR-C124910XX were very poor; no peaks were observed in STD1 and STD2, and the signal-to-noise ratio of the lower limit of quantitation could not reach 10. Typical chromatograms are shown below. Figure 3 .

[0104] Experimental Example 2

[0105] The extraction was performed using liquid-liquid extraction. Simultaneously, nine anticoagulant drugs and ticagrelor active metabolites in plasma were detected using the same chromatographic mass spectrometry system.

[0106] Step 1: Take 100 μL of plasma sample and accurately add 10 μL of internal standard solution (the internal standard solution is prepared with 50% methanol and water, containing warfarin-d5, clopidogrel-13C6, rivaroxaban-d4, edoxaban-d6, dabigatran-d4, apixaban-13C8, rosuvastatin-d3, atorvastatin-d5, and ticagrelor-d7, with internal standard concentrations of 400 ng / mL, 40 ng / mL, 200 ng / mL, 200 ng / mL, 200 ng / mL, 300 ng / mL, 10 ng / mL, 10 ng / mL, and 400 ng / mL, respectively). Accurately add 100 μL of 1% formic acid aqueous solution, vortex to mix, add 1 mL of ethyl acetate, vortex for 3 min, centrifuge at 14000 rpm at 4℃ for 5 min, and take 900 μL of supernatant.

[0107] Step 2: Dry with nitrogen gas, then precisely add 50 μL of 2% acetonitrile aqueous solution to redissolve, and vortex to mix.

[0108] Step 3: Inject the sample into the liquid chromatography-mass spectrometry (LC-MS) system for analysis. Gradient elution was performed using the same elution program as in Step 2 of Example 1. The autosampler temperature was 8°C, the C18 column was an Xselect T3 column with a column temperature of 40°C, the injection volume was 10 μL, and the flow rate was 0.6 mL / min. Detection was performed under the same mass spectrometry conditions as in Step 2 of Example 1.

[0109] The calibration samples were treated using the steps described above, but the responses for dabigatran and edoxaban were poor. A typical chromatogram using ethyl acetate as the extraction reagent and adding 1% formic acid is shown below. Figure 4 .

[0110] When attempts were made to replace the extraction reagent in step 1 with, for example, tert-butyl methyl ether or ethyl acetate and tert-butyl methyl ether in different proportions (1 / 1, 6 / 4, 7 / 3, 8 / 2), and to add different proportions of additives such as 0.5%–5% formic acid, the responses of dabigatran and edoxaban did not improve. This demonstrates that these commonly used pretreatment methods cannot simultaneously achieve the required trough concentrations for each of these 10 compounds.

[0111] Based on the chemical structure and properties of 10 analytes, including warfarin, and through numerous inventive experiments, this invention ultimately proves that ZnSO4 solution and solid-phase extraction plates can simultaneously analyze warfarin, clopidogrel, rivaroxaban, edoxaban, dabigatran, apixaban, rosuvastatin, atorvastatin, ticagrelor, and its metabolite AR-C124910XX, all with very low limits of quantitation (see Example 2 for details).

[0112] To significantly improve the sensitivity of dabigatran, rosuvastatin, and atorvastatin, and to improve the peak shape of dabigatran, this invention, through multiple optimization experiments and verifications, added 0.1%–1% formic acid as an additive to the pretreatment reagent, namely the ZnSO4-containing internal standard solution. The presence of this additive significantly improved the extraction efficiency of dabigatran, rosuvastatin, atorvastatin, rivaroxaban, etc., meeting the requirements for the lower limit of quantitation (LOQ), which would otherwise not be met. Simultaneously, the peak shape of dabigatran was significantly improved. A comparison of results before and after adding 0.1% of the additive to the internal standard solution is shown in the figure. Figure 6 As shown in Table 2, different zinc sulfate precipitating reagents were prepared by adding different proportions of formic acid to the zinc sulfate solution. 20 μL of the lower limit of quantitation working solution was mixed with 180 μL of blank plasma to prepare plasma spiked samples with the lower limit of quantitation concentration. The detection results after protein precipitation treatment with different concentrations of formic acid are compared in Table 2.

[0113] Table 2 Comparison of detection results after protein precipitation with different concentrations of formic acid.

[0114]

[0115] Experimental Example 3

[0116] This experimental example uses the same chromatography-mass spectrometry system to simultaneously detect nine anticoagulant drugs and ticagrelor active metabolites in plasma.

[0117] Step 1: Take 100 μL of plasma sample and accurately add 200 μL of internal standard solution (containing 0.1% formic acid additive, the concentration of ZnSO4 in the internal standard solution is 0.2M, the internal standard solution contains warfarin-d5, clopidogrel-13C6, rivaroxaban-d4, edoxaban-d6, dabigatran-d4, apixaban-13C8, rosuvastatin-d3, atorvastatin-d5, ticagrelor-d7, the contents of the internal standard are 40 ng / mL, 4 ng / mL, 20 ng / mL, 20 ng / mL, 20 ng / mL, 30 ng / mL, 1 ng / mL, 1 ng / mL, 40 ng / mL, respectively), vortex for 3 min, centrifuge at 14000 rpm at 4℃ for 10 min, and take the supernatant;

[0118] Step 2: Take 200 μL of methanol to activate the solid-phase extraction plate, and then use 200 μL of water to balance the solid-phase extraction plate; take 280 μL of the sample supernatant from Step 1 and add it to the activated solid-phase extraction plate. Use the solid-phase extraction device to maintain an elution rate of 1-2 drops / second for further extraction and purification.

[0119] Step 3: After dilution with water, the sample was injected into the liquid chromatography-mass spectrometry (LC-MS) system for analysis. The gradient elution program was as follows: 0-0.2 min, 2% B; 0.2-1.5 min, 2% B-55% B; 1.5-4.5 min, 55% B-95% B; 4.5-6 min, 95% B; 6-7.5 min, 2% B. The autosampler temperature was 8℃, the C18 column used was an Xselect T3 column with a column temperature of 40℃, the injection volume was 5 μL, and the flow rate was 0.6 mL / min. Electrospray ionization in positive ion mode was used, with multiple reaction monitoring (MRM) mass spectrometry. Further, the mass spectrometry conditions were: ionization voltage 5.5 kV; source temperature 550℃; spray gas GS1 60 psi; auxiliary heater GS2 65 psi; curtain gas 35 psi; collision gas 9.

[0120] When injecting a mixed series of standards, the standard curves for ticagrelor and AR-C124910XX were found to be non-linear. When injecting individual standards of both, MRM ion channel interference was observed between ticagrelor and its active metabolite AR-C124910XX. When ticagrelor standard was injected alone, and then the MRM channel peak of metabolite AR-C124910XX was extracted, a distinct peak was observed with the same retention time as ticagrelor. When AR-C124910XX standard was injected alone, and then the MRM channel peak of ticagrelor was extracted, a strongly responsive peak was observed with the same retention time as AR-C124910XX. Typical chromatograms are shown below. Figure 1 (Mobile phase A is 0.1% formic acid aqueous solution, and mobile phase B is acetonitrile). Ticagrelor and AR-C124910XX have very similar structures and retention times. To solve the problem of interference between channels, it is necessary to completely separate their chromatographic peaks.

[0121] When acetonitrile was used as mobile phase B and 0.1% formic acid aqueous solution as mobile phase A, attempts were made to flatten the gradient at the peak positions of the two phases, but complete separation was still not achieved. For example, the elution gradient was set to 0-0.5 min, 10% B; 0.5-2.5 min, 45% B; 2.5-4 min, 65% B; 4-4.1 min, 95% B; 4.1-5.5 min, 95% B; 5.5-5.6 min, 10% B; 5.6-7 min, 10% B. A typical chromatogram is shown below. Figure 7.

[0122] When methanol, which has relatively weak elution ability, is used as mobile phase B and 0.1% formic acid water is used as mobile phase A, the peak shape will become very wide and thick after the gradient is changed to separate the two chromatograms. When the content of the analyte is low, it will affect the accurate quantification of the analyte.

[0123] Mobile phase B was prepared by mixing acetonitrile and methanol in a ratio of 3 / 7 to 1 / 9. The mobile phase gradient was optimized to achieve complete chromatographic separation of the two compounds while ensuring sharp and symmetrical peaks. The chromatograms of ticagrelor and its metabolite AR-C124910XX are as follows: [Image of mobile phase B]. Figure 5 As shown. Figure 5 It is evident that the problem of channel interference between ticagrelor and its active metabolite AR-C124910XX was resolved before and after changing the mobile phase B to 90% methanol. Therefore, this invention confirms the use of methanol and acetonitrile in the mobile phase, with the addition of an additive of 0.1% to 1% formic acid (pH < 2) (see Examples 1 and 2 below for details).

[0124] Example 1: The detection method of the present invention

[0125] Step 1: Accurately add 200 μL of internal standard solution (containing 0.1% formic acid additive, the concentration of ZnSO4 in the internal standard solution is 0.2 M) to 100 μL of plasma sample. The concentrations of the internal standard solution are as follows: thiamethoxam-d5: 40 ng / mL; clopidogrel-13C6: 4 ng / mL; rivaroxaban-d4: 20 ng / mL; edoxaban-d6: 20 ng / mL; dabigatran-d4: 20 ng / mL; apixaban-13C8: 30 ng / mL; rosuvastatin-d3: 1 ng / mL; atorvastatin-d5: 1 ng / mL; ticagrelor-d7: 40 ng / mL. Therefore, in step 1, the internal standard solution contains warfarin-d5, clopidogrel-13C6, rivaroxaban-d4, edoxaban-d6, dabigatran-d4, apixaban-13C8, rosuvastatin-d3, atorvastatin-d5, and ticagrelor-d7, with internal standard concentrations of 40 ng / mL, 4 ng / mL, 20 ng / mL, 20 ng / mL, 20 ng / mL, 30 ng / mL, 1 ng / mL, 1 ng / mL, and 40 ng / mL, respectively. The solution is vortexed for 3 min, centrifuged at 14000 rpm at 4℃ for 10 min, and the supernatant is collected.

[0126] Step 2: Take 200 μL of methanol to activate the solid-phase extraction plate, and then use 200 μL of water to balance the solid-phase extraction plate; take 280 μL of the sample supernatant from Step 1 and add it to the activated solid-phase extraction plate. Use the solid-phase extraction device to maintain an elution rate of 1-2 drops / second for further extraction and purification.

[0127] Step 3: After dilution with water, the sample was injected into the liquid chromatography-mass spectrometry (LC-MS) instrument for analysis. Mobile phase A was water, and mobile phase B was methanol / acetonitrile at a 9:1 ratio (both containing 0.1% formic acid). The gradient elution program was: 0-0.2 min, 2% B; 0.2-1.5 min, 2% B-55% B; 1.5-4.5 min, 55% B-95% B; 4.5-6 min, 95% B; 6-7.5 min, 2% B. The autosampler temperature was 8℃, the column temperature was 40℃, and the injection volume was 5 μL. The C18 column used was an Xselect T3 column, with a column temperature of 40℃, a sample tray temperature of 8℃, a flow rate of 0.6 mL / min, and an injection volume of 5 μL. Multiple reaction monitoring (MRM) mass spectrometry was used in electrospray ionization positive ion mode. Furthermore, the mass spectrometry conditions were as follows: ionization voltage of 5.5 kV; source temperature of 550 °C; spray gas GS1 of 60 psi; auxiliary heater GS2 of 65 psi; curtain gas of 35 psi; and collision gas of 9.

[0128] Typical chromatograms of 10 compounds are shown below. Figure 8 As shown.

[0129] Example 2: Detection limits of the detection method of the present invention for the above-mentioned 9 drugs and ticagrelor metabolite AR-C124910XX

[0130] The detection limits for the above-mentioned drugs are as follows: 2 ng / mL warfarin, 0.2 ng / mL clopidogrel, 1 ng / mL rivaroxaban, 1 ng / mL edoxaban, 1 ng / mL dabigatran, 1.5 ng / mL apixaban, 0.25 ng / mL rosuvastatin, 0.25 ng / mL atorvastatin, 2 ng / mL ticagrelor, and 1 ng / mL ticagrelor active metabolite AR-C124910XX.

[0131] Using the method of this invention, low concentrations of warfarin, clopidogrel, rivaroxaban, edoxaban, dabigatran, apixaban, rosuvastatin, atorvastatin, ticagrelor, and its metabolite AR-C124910XX are added to plasma to simulate a real plasma sample, namely 2 ng / mL warfarin, 0.2 ng / mL clopidogrel, 1 ng / mL rivaroxaban, 1 ng / mL edoxaban, 1 ng / mL dabigatran, 1.5 ng / mL apixaban, 0.25 ng / mL rosuvastatin, 0.25 ng / mL atorvastatin, 2 ng / mL ticagrelor, and 1 ng / mL ticagrelor active metabolite AR-C124910XX. The detection limits of this method for warfarin, clopidogrel, rivaroxaban, edoxaban, dabigatran, apixaban, rosuvastatin, atorvastatin, ticagrelor, and its metabolite AR-C124910XX were investigated. The specific steps are as follows:

[0132] Step 1: Add a low-concentration standard solution to the plasma, with the volume not exceeding 10% of the plasma volume to avoid affecting the plasma matrix. Prepare a plasma sample containing warfarin, clopidogrel, rivaroxaban, edoxaban, dabigatran, apixaban, rosuvastatin, atorvastatin, ticagrelor, and its metabolite AR-C124910XX. Specifically, the concentrations are: 2 ng / mL warfarin, 0.2 ng / mL clopidogrel, 1 ng / mL rivaroxaban, 1 ng / mL edoxaban, 1 ng / mL dabigatran, 1.5 ng / mL apixaban, 0.25 ng / mL rosuvastatin, 0.25 ng / mL atorvastatin, 2 ng / mL ticagrelor, and 1 ng / mL ticagrelor active metabolite AR-C124910XX.

[0133] Step 2: Add the internal standard solution to the prepared plasma sample using the same method as in Step 1 of Example 1;

[0134] Step 3: Further extraction and purification are carried out by solid-phase extraction using the same method as in Step 2 of Example 1;

[0135] Step 4: Perform chromatographic analysis using the same method as in Step 3 of Example 1.

[0136] The signal-to-noise ratios (SNRs) of the chromatographic peaks in the detection results were analyzed. The SNRs of warfarin (2 ng / mL), clopidogrel (0.2 ng / mL), rivaroxaban (1 ng / mL), edoxaban (1 ng / mL), dabigatran (1.5 ng / mL), apixaban (0.25 ng / mL), rosuvastatin (0.25 ng / mL), atorvastatin (0.25 ng / mL), ticagrelor (2 ng / mL), and the active metabolite AR-C124910XX of ticagrelor (1 ng / mL) were all greater than 10, meeting the requirements for quantification. This demonstrates that the detection method of this invention can meet the detection limits for these drugs. Typical chromatograms are shown below. Figure 9 The specific signal-to-noise ratio values ​​for the limits of quantitation of each compound are shown in Table 3.

[0137] Table 3. Lower limits of quantification for 9 drugs and ticagrelor metabolite AR-C124910XX

[0138] Serial Number name Lower limit of quantitation Signal-to-noise ratio 1 warfarin 2ng / mL 50.5 2 Clopidogrel 0.2 ng / mL 35.6 3 Rivaroxaban 1ng / mL 97.9 4 Aidoshaban 1ng / mL 112.7 5 Dabiga Group 1ng / mL 86.9 6 Apixaban 1.5 ng / mL 62.9 7 rosuvastatin 0.25 ng / mL 12.4 8 Atorvastatin 0.25 ng / mL 31.7 9 Ticagrelor 2ng / mL 56 10 AR-C124910XX 1ng / mL 38

[0139] The prior patent CN114755348A established a method for detecting warfarin alone, with a limit of quantification of 200 ng / mL; while the limit of quantification of warfarin in this invention is 2 ng / mL.

[0140] The prior patent CN113092628A established a method for rivaroxaban, edoxaban, apixaban, and dabigatran, which used methanol or acetonitrile as the precipitating agent. The linear range of the four compounds in that invention was 2-500 ng / mL. In this invention, the linear range of dabigatran, rivaroxaban, and edoxaban is 1-1000 ng / mL, with the lower limit of quantitation being twice as low as that of the prior patent, and the upper limit also twice as high.

[0141] The prior patent CN115372499A established a method for ticagrelor and AR-C124910XX. In that invention, methanol or acetonitrile was selected as the precipitant. The linear range of ticagrelor was 11.70-2500 ng / mL, and the linear range of the metabolite AR-C124910XX was 11.72-2000 ng / mL. In contrast, the linear range of ticagrelor in this invention is 2-2000 ng / mL, and the lower limit of quantification is about 1 / 5 of that of the prior patent. The linear range of the metabolite AR-C124910XX in this invention is 1-1000 ng / mL, which is 1000 times the linear range, and the lower limit of quantification is 1 / 10 of that of the prior patent.

[0142] Furthermore, as shown in Table 3, the signal-to-noise ratios (SNRs) of all 10 compounds far exceeded 10. According to industry consensus, the concentration with an SNR equal to 10 is the limit of quantitation. Using the method of this invention, the SNR was 50.5 for warfarin at a concentration of 2 ng / mL; 35.6 for clopidogrel at a concentration of 0.2 ng / mL; 97.9 for rivaroxaban at a concentration of 1 ng / mL; and 112.7 for edoxaban at a concentration of 1 ng / mL. The signal-to-noise ratio (SNR) was 86.9 at a dabigatran concentration of 1 ng / mL; 62.9 at a apixaban concentration of 1.5 ng / mL; 12.4 at a rosuvastatin concentration of 0.25 ng / mL; 31.7 at a atorvastatin concentration of 0.25 ng / mL; 56 at a ticagrelor concentration of 2 ng / mL; and 38 at a AR-C124910XX concentration of 1 ng / mL. Based on such a high signal-to-noise ratio, when the signal-to-noise ratio equals 10, the limits of quantification (LOQ) for these 10 compounds should be as follows: warfarin 0.396 ng / mL; clopidogrel 0.056 ng / mL; rivaroxaban 0.102 ng / mL; edoxaban 0.089 ng / mL; dabigatran 0.115 ng / mL; apixaban 0.238 ng / mL; rosuvastatin 0.202 ng / mL; atorvastatin 0.079 ng / mL; ticagrelor 0.357 ng / mL; and AR-C124910XX 0.263 ng / mL.

[0143] Example 3: Linear regression equation for the detection of warfarin, clopidogrel, rivaroxaban, edoxaban, dabigatran, apixaban, rosuvastatin, atorvastatin, ticagrelor, and its metabolite AR-C124910XX.

[0144] According to the testing requirements, warfarin, clopidogrel, rivaroxaban, edoxaban, dabigatran, apixaban, rosuvastatin, atorvastatin, ticagrelor, and its metabolite AR-C124910XX need to show good linearity within the detection range. A series of concentrations of the nine drugs and the ticagrelor metabolite AR-C124910XX were added to plasma, and linear regression curves and equations for each drug were plotted.

[0145] The series concentrations of each drug are shown below:

[0146] The concentrations of warfarin are 2 ng / mL, 4 ng / mL, 10 ng / mL, 20 ng / mL, 40 ng / mL, 80 ng / mL, 200 ng / mL, 400 ng / mL, 800 ng / mL, and 2000 ng / mL;

[0147] The concentrations of clopidogrel are 0.2 ng / mL, 0.4 ng / mL, 1 ng / mL, 2 ng / mL, 4 ng / mL, 8 ng / mL, 20 ng / mL, 40 ng / mL, 80 ng / mL, and 200 ng / mL;

[0148] The concentrations of rivaroxaban are 1 ng / mL, 2 ng / mL, 5 ng / mL, 10 ng / mL, 20 ng / mL, 40 ng / mL, 100 ng / mL, 200 ng / mL, 400 ng / mL, and 1000 ng / mL.

[0149] The concentrations of edoxaban are 1 ng / mL, 2 ng / mL, 5 ng / mL, 10 ng / mL, 20 ng / mL, 40 ng / mL, 80 ng / mL, 200 ng / mL, 400 ng / mL, and 1000 ng / mL;

[0150] The concentrations of dabigatran were 1 ng / mL, 2 ng / mL, 5 ng / mL, 10 ng / mL, 20 ng / mL, 40 ng / mL, 80 ng / mL, 200 ng / mL, 400 ng / mL, and 1000 ng / mL.

[0151] The concentrations of apixaban are 1.5 ng / mL, 3 ng / mL, 7.5 ng / mL, 15 ng / mL, 30 ng / mL, 60 ng / mL, 150 ng / mL, 300 ng / mL, 600 ng / mL, and 1500 ng / mL;

[0152] The concentrations of rosuvastatin are 0.25 ng / mL, 0.5 ng / mL, 1 ng / mL, 2 ng / mL, 5 ng / mL, 10 ng / mL, 20 ng / mL, and 50 ng / mL;

[0153] Atorvastatin concentrations are 0.25 ng / mL, 0.5 ng / mL, 1 ng / mL, 2 ng / mL, 5 ng / mL, 10 ng / mL, 20 ng / mL, and 50 ng / mL;

[0154] The concentrations of ticagrelor are 2 ng / mL, 4 ng / mL, 10 ng / mL, 20 ng / mL, 40 ng / mL, 80 ng / mL, 200 ng / mL, 400 ng / mL, 800 ng / mL, and 2000 ng / mL;

[0155] The concentrations of AR-C124910XX are 1 ng / mL, 2 ng / mL, 5 ng / mL, 10 ng / mL, 20 ng / mL, 40 ng / mL, 80 ng / mL, 200 ng / mL, 400 ng / mL, and 1000 ng / mL.

[0156] The specific steps are as follows:

[0157] Step 1: Add a series of standard solutions of varying concentrations to the plasma, ensuring the volume does not exceed 10% of the plasma volume to avoid affecting the plasma matrix. Prepare plasma samples containing different concentrations of warfarin, clopidogrel, rivaroxaban, edoxaban, dabigatran, apixaban, rosuvastatin, atorvastatin, ticagrelor, and its metabolite AR-C124910XX. Specifically, the concentrations are 2-2000 ng / mL warfarin and 0.2-200 ng / mL standard solutions. Clopidogrel, 1-1000 ng / mL rivaroxaban, 1-1000 ng / mL edoxaban, 1-1000 ng / mL dabigatran, 1.5-1500 ng / mL apixaban, 0.25-50 ng / mL rosuvastatin, 0.25-50 ng / mL atorvastatin, 2-2000 ng / mL ticagrelor, 1-1000 ng / mL AR-C124910XX;

[0158] Step 2: Add the internal standard solution to the prepared plasma samples of the series concentrations using the same method as in Step 1 of Example 1;

[0159] Step 3: Further extraction and purification are carried out by solid-phase extraction using the same method as in Step 2 of Example 1;

[0160] Step 4: Perform chromatographic analysis using the same method as in Step 3 of Example 1, and analyze the detection results. The results show that warfarin (2-2000 ng / mL), clopidogrel (2-200 ng / mL), rivaroxaban (1-1000 ng / mL), edoxaban (1-1000 ng / mL), dabigatran (1-1000 ng / mL), apixaban (1.5-1500 ng / mL), rosuvastatin (0.25-50 ng / mL), atorvastatin (0.25-50 ng / mL), ticagrelor (2-2000 ng / mL), and AR-C124910XX (1-1000 ng / mL) exhibit good linearity, proving that the invention can meet the detection requirements.

[0161] Table 4 Standard Curve Equation Table

[0162] Serial Number name Linear lower limit Linear upper limit Standard Curve Equation 1 warfarin 2ng / mL 2000ng / mL y=0.00479x+-0.00172(r=0.99605) 2 Clopidogrel 0.2 ng / mL 200ng / mL y=0.01639x+0.00714(r=0.99690) 3 Rivaroxaban 1ng / mL 1000ng / mL y=0.02525x+0.04474(r=0.99843) 4 Apixaban 1.5 ng / mL 1500ng / mL <![CDATA[y=0.00417x+2.69790e -4 (r=0.99879)]]> 5 Dabiga Group 1ng / mL 1000ng / mL <![CDATA[y=0.01223x+8.51209e -4 (r=0.99670)]]> 6 Aidoshaban 1ng / mL 1000ng / mL <![CDATA[y=0.00583x+-2.15592e -4 (r=0.99855)]]> 7 Ticagrelor 2ng / mL 2000ng / mL <![CDATA[y=0.00409x+-9.9905e -4 (r=0.99938)]]> 8 AR-C124910XX 1ng / mL 1000ng / mL <![CDATA[y=0.01136x+8.93883e -4 (r=0.9992)]]> 9 Atorvastatin 0.25 ng / mL 50 ng / mL <![CDATA[y=6.67622e -4 x+-3.9859e -4 (r=0.99830)]]> 10 rosuvastatin 0.25 ng / mL 50 ng / mL y=0.01955x+-0.01356(r=0.99431)

[0163] Example 4: Accuracy and precision of detecting 9 drugs and ticagrelor metabolite AR-C124910XX

[0164] Using the method of this invention, high, medium, and low concentrations of the drug were added to plasma to simulate real plasma samples, and the accuracy and precision of the method at different concentrations were examined.

[0165] Warfarin concentrations are 5 ng / mL, 30 ng / mL, 300 ng / mL and 1500 ng / mL;

[0166] Clopidogrel concentrations are 0.5 ng / mL, 3 ng / mL, 30 ng / mL and 150 ng / mL;

[0167] The concentrations of rivaroxaban were 2.5 ng / mL, 15 ng / mL, 150 ng / mL and 750 ng / mL;

[0168] The concentrations of edoxaban were 2.5 ng / mL, 15 ng / mL, 150 ng / mL and 750 ng / mL;

[0169] The concentrations of dabigatran were 2.5 ng / mL, 15 ng / mL, 150 ng / mL and 750 ng / mL;

[0170] The concentrations of apixaban were 3.75 ng / mL, 22.5 ng / mL, 225 ng / mL and 1125 ng / mL;

[0171] The concentrations of rosuvastatin were 0.75 ng / mL, 7.5 ng / mL, and 37.5 ng / mL;

[0172] Atorvastatin concentrations were 0.75 ng / mL, 7.5 ng / mL, and 37.5 ng / mL;

[0173] The concentrations of ticagrelor were 5 ng / mL, 30 ng / mL, 300 ng / mL and 1500 ng / mL;

[0174] The concentrations of AR-C124910XX were 2.5 ng / mL, 15 ng / mL, 150 ng / mL and 750 ng / mL.

[0175] Specifically, the steps include the following:

[0176] Step 1: Add high, medium, and low concentration standard solutions to the plasma, ensuring the volume does not exceed 10% of the plasma volume to avoid affecting the plasma matrix. Prepare plasma samples containing different concentrations of warfarin, clopidogrel, rivaroxaban, edoxaban, dabigatran, apixaban, rosuvastatin, atorvastatin, ticagrelor, and its metabolite AR-C124910XX. Prepare three batches of this simulated plasma sample consecutively. These three batches (except for rosuvastatin and atorvastatin, which each contain three concentrations, the others each contain four concentrations) Concentrations (each concentration repeated 6 times) were used to simulate plasma samples containing warfarin, clopidogrel, rivaroxaban, edoxaban, dabigatran, apixaban, rosuvastatin, atorvastatin, ticagrelor, and its metabolite AR-C124910XX, with the following concentrations in order: warfarin at 5 ng / mL, 30 ng / mL, 300 ng / mL, and 1500 ng / mL; clopidogrel at 0.5 ng / mL, 3 ng / mL, 30 ng / mL, and 150 ng / mL; rivaroxaban at 6 times. The concentrations of benzo[a]ban were 2.5 ng / mL, 15 ng / mL, 150 ng / mL, and 750 ng / mL; the concentrations of edoxaban were 2.5 ng / mL, 15 ng / mL, 150 ng / mL, and 750 ng / mL; the concentrations of dabigatran were 2.5 ng / mL, 15 ng / mL, 150 ng / mL, and 750 ng / mL; and the concentrations of apixaban were 3.75 ng / mL, 22.5 ng / mL, 225 ng / mL, and 1125 ng / mL. L; the concentrations of rosuvastatin were 0.75 ng / mL, 7.5 ng / mL, and 37.5 ng / mL; the concentrations of atorvastatin were 0.75 ng / mL, 7.5 ng / mL, and 37.5 ng / mL; the concentrations of ticagrelor were 5 ng / mL, 30 ng / mL, 300 ng / mL, and 1500 ng / mL; the concentrations of AR-C124910XX were 2.5 ng / mL, 15 ng / mL, 150 ng / mL, and 750 ng / mL.

[0177] Step 2: Add the internal standard solution to the simulated plasma sample using the same method as in Step 1 of Example 1;

[0178] Step 3: Further extraction and purification are carried out by solid-phase extraction using the same method as in Step 2 of Example 1;

[0179] Step 4: Detection was performed using a liquid chromatography-mass spectrometry (LC-MS) analyzer. The chromatographic column used was an Xselect T3 LC column, with a column temperature of 40℃, a sample tray temperature of 8℃, a flow rate of 0.6 mL / min, and an injection volume of 5 μL.

[0180] The mobile phases were an aqueous solution containing formic acid and a mixture of acetonitrile and methanol containing formic acid; the aqueous phase was an aqueous solution containing 0.1% formic acid, and the organic phase was an acetonitrile / methanol (v / v, 1 / 9) mixture containing 0.1% formic acid.

[0181] Liquid phase conditions (elution gradient):

[0182] Mobile phase A is a 0.1% formic acid aqueous solution, and mobile phase B is acetonitrile / methanol (v / v, 1 / 9) (containing 0.1% formic acid);

[0183] The gradient elution program was as follows: 0-0.2 min, 2% B; 0.2-1.5 min, 2% B-55% B; 1.5-4.5 min, 55% B-95% B; 4.5-6 min, 95% B; 6.1-7.5 min, 2% B.

[0184] Mass spectrometry conditions are:

[0185] In electrospray ionization positive ion mode, multiple reaction monitoring (MRM) mass spectrometry was used. The ionization voltage was 5.5 kV; the source temperature was 550 °C; the spray gas GS1 was 60 psi; the auxiliary heater GS2 was 65 psi; the curtain gas was 35 psi; and the collision gas was 9 psi.

[0186] The ion pairs used for quantitative analysis and monitoring are:

[0187] Warfarin, m / z 309>251(+), declustering voltage: 130V, collision voltage: 25V;

[0188] Clopidogrel, m / z 322.3>155.2(+), declustering voltage: 100V, collision voltage: 40V;

[0189] Rivaroxaban, m / z 436>145.1(+), declustering voltage: 90V, collision voltage: 30V;

[0190] Edoshaban, m / z 548.2>152.2(+), declustering voltage: 100V, collision voltage: 25V;

[0191] Darbigat group, m / z 472.2>306.3(+), declustering voltage: 120V, collision voltage: 23V;

[0192] Apixaban, m / z 460.1>199.2(+), declustering voltage: 80V, collision voltage: 30V;

[0193] Rosuvastatin, m / z 482.3>258.3(+), declustering voltage: 110V, collision voltage: 40V;

[0194] Atorvastatin, m / z 559.2>440.1(+), declustering voltage: 80V, collision voltage: 42V;

[0195] Ticagrelor, m / z 523.2>293.3(+), declustering voltage: 90V, collision voltage: 30V;

[0196] AR-C124900XX, m / z 479.1>152.9(+), declustering voltage: 120V, collision voltage: 43V;

[0197] Step 5: Using the standard curve in Example 4, calculate the contents of phloretin, clopidogrel, rivaroxaban, edoxaban, dabigatran, apixaban, rosuvastatin, atorvastatin, ticagrelor, and metabolite AR-C124910XX in the simulated plasma sample, and calculate the precision and accuracy between different concentrations and 6 batches.

[0198] The series of different concentrations of warfarin, clopidogrel, rivaroxaban, edoxaban, dabigatran, apixaban, rosuvastatin, atorvastatin, ticagrelor and its metabolite AR-C124910XX are shown in Table 5 below.

[0199] Table 5. Quality control concentrations of 9 drugs and ticagrelor metabolite AR-C124910XX

[0200] Serial Number name LQC MQC1 MQC2 HQC 1 warfarin 5ng / mL 30ng / mL 300ng / mL 1500ng / mL 2 Clopidogrel 0.5 ng / mL 3ng / mL 30ng / mL 150 ng / mL 3 Rivaroxaban 2.5 ng / mL 15ng / mL 150 ng / mL 750ng / mL 4 Apixaban 3.75 ng / mL 22.5 ng / mL 225ng / mL 1125ng / mL 5 Dabiga Group 2.5 ng / mL 15ng / mL 150 ng / mL 750ng / mL 6 Aidoshaban 2.5 ng / mL 15ng / mL 150 ng / mL 750ng / mL 7 Tigrose 5ng / mL 30ng / mL 300ng / mL 1500ng / mL 8 AR-C124910XX 2.5 ng / mL 15ng / mL 150 ng / mL 750ng / mL 9 Atorvastatin N / A 0.75 ng / mL 7.5 ng / mL 37.5 ng / mL 10 Rosuvastatin N / A 0.75 ng / mL 7.5 ng / mL 37.5 ng / mL

[0201] The results of precision and accuracy calculations for warfarin, clopidogrel, rivaroxaban, edoxaban, dabigatran, apixaban, rosuvastatin, atorvastatin, ticagrelor and its metabolite AR-C124910XX at different concentrations and in three batches are shown in Tables 6-15 below.

[0202] Table 6. Results of Warfarin Accuracy and Precision

[0203]

[0204]

[0205] Table 7. Accuracy and Precision Results of Clopidogrel

[0206]

[0207]

[0208]

[0209] Table 8. Accuracy and Precision Results of Rivaroxaban

[0210]

[0211]

[0212]

[0213] Table 9. Accuracy and Precision Results of Edoxaban

[0214]

[0215]

[0216] Table 10. Accuracy and precision results of dabigatran.

[0217]

[0218]

[0219]

[0220] Table 11 Accuracy and precision results of apixaban

[0221]

[0222]

[0223]

[0224] Table 12 Accuracy and Precision Results of Ticagrelor

[0225]

[0226]

[0227] Table 13 Accuracy and precision results of ticagrelor (AR-C124910XX)

[0228]

[0229]

[0230]

[0231] Table 14. Accuracy and precision results of rosuvastatin

[0232]

[0233]

[0234]

[0235] Table 15 Accuracy and Precision Results of Atorvastatin

[0236]

[0237]

[0238] The results in Tables 6-15 show that the method of the present invention for detecting warfarin, clopidogrel, rivaroxaban, edoxaban, dabigatran, apixaban, rosuvastatin, atorvastatin, ticagrelor, and its metabolite AR-C124910XX has an accuracy of 85-115%, indicating good accuracy, and a precision of less than 12%, indicating good precision.

[0239] The specific embodiments of the present invention have been described above. It should be understood that the present invention is not limited to the specific embodiments described above, and those skilled in the art can make various modifications or variations within the scope of the claims, which do not affect the essence of the present invention.

Claims

1. A highly sensitive method for simultaneous detection of nine anticoagulant drugs and the active metabolite of ticagrelor AR-C124910XX in plasma. It is characterized in that The nine anticoagulant drugs are warfarin, clopidogrel, rivaroxaban, edoxaban, dabigatran, apixaban, rosuvastatin, atorvastatin, and ticagrelor; The method comprises the following steps: S1. Take a plasma sample, add an internal standard solution, mix, centrifuge, and take the supernatant; the internal standard solution is prepared by mixing the internal standard in ZnSO containing formic acid. 4 in solution; S2, adding the supernatant to the activated solid phase extraction plate, and further extracting and purifying using a solid phase extraction device; S3, injecting the eluate into a liquid chromatography-mass spectrometer for analysis; The mobile phase used in the chromatographic detection includes an aqueous phase and an organic phase, wherein the aqueous phase is an aqueous solution containing 0.1-1 wt.% formic acid, and the organic phase is an acetonitrile / methanol mixture containing 0.1-1 wt.% formic acid, wherein the volume ratio of acetonitrile to methanol in the organic phase is 3 / 7-1 / 9; S4. Calculate the contents of warfarin, clopidogrel, rivaroxaban, edoxaban, dabigatran, apixaban, rosuvastatin, atorvastatin, ticagrelor and metabolite AR-C124910XX in the samples based on the standard curve method.

2. The method according to claim 1, It is characterized in that In step S1, the internal standard solution contains ZnSO 4 The concentration is 0.2M~0.5M, and the content of formic acid is 0.1wt.%~1wt.%.

3. The method according to claim 1, It is characterized in that The internal standards are respectively the isotope internal standards of warfarin, clopidogrel, rivaroxaban, edoxaban, dabigatran, apixaban, rosuvastatin, atorvastatin, and ticagrelor.

4. The method according to claim 3, It is characterized in that The internal standard of warfarin is warfarin-d5; the internal standard of clopidogrel is clopidogrel-13C6; the internal standard of rivaroxaban is rivaroxaban-d4; the internal standard of edoxaban is edoxaban-d6; the internal standard of dabigatran is dabigatran-d4; the internal standard of apixaban is apixaban-13C8; the internal standard of rosuvastatin is rosuvastatin-d3; the internal standard of atorvastatin is atorvastatin-d5; the internal standard of ticagrelor and its active metabolite AR-C124900XX is ticagrelor-d7.

5. The method according to claim 4, It is characterized in that The contents of warfarin-d5, clopidogrel-13C6, rivaroxaban-d4, edoxaban-d6, dabigatran-d4, apixaban-13C8, rosuvastatin-d3, atorvastatin-d5, and ticagrelor-d7 are 40 ng / mL, 4 ng / mL, 20 ng / mL, 20 ng / mL, 20 ng / mL, 30 ng / mL, 1 ng / mL, 1 ng / mL, and 40 ng / mL, respectively.

6. The method according to claim 1, It is characterized in that In step S2, the elution reagent during solid phase extraction is a 70% to 100% methanol solution containing 0.1% to 1% formic acid.

7. The method according to claim 1, It is characterized in that In step S3, the chromatographic column used is a C18 chromatographic column.

8. The detection method according to claim 7, It is characterized in that The C18 chromatographic column is specifically an Xselect T3 chromatographic column, the column temperature of the chromatographic column is 30-50° C., the sample plate temperature is 8-10° C., the flow rate is 0.6 mL / min, and the injection volume is 5 μL.

9. The detection method according to claim 1, It is characterized in that The program of step S3 gradient elution is: 0-0.2min, 2% B; 0.2-1.5min, 2% B-55% B; 1.5-4.5min, 55% B-95% B; 4.5-6min, 95% B; 6.1-7.5min, 2% B. 0-0.2min, 2% B; 0.2-1.5min, 2% B-55% B; 1.5-4.5min, 55% B-95% B; 4.5-6min, 95% B; 6-7.5min, 2% B; B is organic phase; the temperature of the automatic sampler is 8-10°C, the column temperature is 30-50°C, and the injection volume is 5 μL.

10. The detection method according to claim 1, It is characterized in that In step S3, the mass spectrometry condition is to use a mass spectrometry scanning mode of multiple reaction monitoring in an electrospray ionization positive ion mode; The ionization voltage was 5.5 KV; the source temperature was 550 °C; the spray gas GS1 was 60 psi; the auxiliary heater GS2 was 65 psi; the curtain gas was 35 psi; and the collision gas was 9; The ion pairs used for quantitative analysis are: Warfarin, m / z 309>251(+), declustering voltage: 130 V, collision voltage: 25 V; Clopidogrel, m / z 322.3>155.2(+), declustering voltage: 100 V, collision voltage: 40 V; Rivaroxaban, m / z 436>145.1(+), declustering voltage: 90 V, collision voltage: 30 V; Edoxaban, m / z 548.2>152.2(+), declustering voltage: 100 V, collision voltage: 25 V; Dabigatran, m / z 472.2>306.3(+), declustering voltage: 120 V, collision voltage: 23 V; Apixaban, m / z 460.1>199.2(+), declustering voltage: 80 V, collision voltage: 30 V; Rosuvastatin, m / z 482.3>258.3(+), declustering voltage: 110 V, collision voltage: 40 V; Atorvastatin, m / z 559.2>440.1(+), declustering voltage: 80 V, collision voltage: 42 V; Ticagrelor, m / z 523.2>293.3(+), declustering voltage: 90 V, collision voltage: 30 V; AR-C124900XX, m / z 479.1>152.9(+), declustering voltage: 120V, collision voltage: 43V.